Catalog No.
Product Name
Application
Product Information
Citations
-
c-MET Kinase Inhibitor
Capmatinib dihydrochloride hydrate is a potent, orally bioavailable inhibitor of c-Met kinase, exhibiting an IC50 value of 0.13 nM. This selective and ATP-competitive inhibitor disrupts the phosphorylation of c-MET and its downstream signaling pathways, including ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate demonstrates substantial antitumor activity by effectively inhibiting c-MET-dependent tumor cell proliferation, migration, and promoting apoptosis. Primarily metabolized by CYP3A4 and aldehyde oxidase, this compound is instrumental in cancer research focused on targeting c-Met-associated pathways. -
Sialoglycolipid
Ganglioside GM1, a sialoglycolipid, plays a crucial role in neuroprotection through its ability to reduce overactivation of NMDA receptors (NMDAR) while concurrently activating TrkA and ERK1/2 pathways. This compound effectively mitigates oxidative stress, cell apoptosis, and autophagy, making it valuable for studying various neurodegenerative conditions. Research applications include investigations into traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease, highlighting its significance in understanding neuroprotective mechanisms. -
FLT3 Inhibitor
Quizartinib dihydrochloride is a potent and selective second-generation type II FLT3 tyrosine kinase inhibitor. Demonstrating a Kd of 1.6 nM, it effectively inhibits autophosphorylation of both wild-type FLT3 and FLT3-ITD in MV4-11 cells, with IC50 values of 4.2 nM and 1.1 nM, respectively. This compound is also suitable for the development of PROTAC FLT3 degraders when linked to the VHL ligand, and it has been shown to induce apoptosis in target cells. -
Pan-FLT3/Pan-BTK Inhibitor
Luxeptinib is a first-in-class, non-covalent pan-FLT3 and pan-BTK inhibitor that exhibits potent oral activity. This compound effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells, making it a significant tool for cancer research. Its dual-targeting mechanism positions Luxeptinib as a potential therapeutic candidate in the treatment of hematological malignancies. -
ALK/FAK/ROS1 Multikinase Inhibitor
APG-2449 is an orally active inhibitor targeting BCL-2 and multikinase pathways, specifically ALK, FAK, and ROS1. It demonstrates potent antitumor activity by reducing cell viability and enhancing apoptosis in acute myeloid leukemia cells in vitro. APG-2449 effectively decreases the activation of FAK and its downstream signaling effectors. This compound is suitable for research applications in various malignancies, including mesothelioma, non-small cell lung cancer, ovarian cancer, and other hematologic and solid tumors. -
Src Inhibitor
Peruvoside is a potent Src inhibitor that also targets PI3K, JNK, STAT, and EGFR pathways. This compound induces apoptosis and autophagy, demonstrating a broad spectrum of anticancer activity in various cancers, including breast, lung, liver, and leukemia. Additionally, Peruvoside exhibits significant antiviral activity against positive-sense RNA viruses and can sensitize Gefitinib-resistant tumor cells, such as A549, PC9/gef, and H1975, to Gefitinib treatment. -
ALKBH5 Inhibitor
W23-1006 is a selective and covalent inhibitor of ALKBH5, targeting the C200 residue with an IC50 of 3.848 μM. This compound exhibits approximately 30-fold and 8-fold greater inhibitory activity against ALKBH5 compared to FTO and ALKBH3, respectively. W23-1006 is particularly valuable for research applications focusing on triple-negative breast cancer (TNBC), enabling studies on the role of ALKBH5 in tumor biology and potential therapeutic strategies. -
c-MET Kinase Inhibitor
Capmatinib dihydrochloride is a selective, ATP-competitive inhibitor of the c-MET kinase, exhibiting an IC50 of 0.13 nM. This compound effectively inhibits the phosphorylation of c-MET and its downstream effector pathways, including ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride demonstrates potent antitumor activity by suppressing c-MET-dependent tumor cell proliferation and migration, while also inducing apoptosis. The drug undergoes significant metabolism via CYP3A4 and aldehyde oxidase, making it relevant for studies involving c-MET-driven malignancies. -
EGFR Inhibitor
EGFR-IN-86 is a potent EGFR inhibitor, exhibiting an IC50 of 1.5 nM. It demonstrates significant biological activity against glioblastoma by inducing apoptosis and causing cell cycle arrest in the G2/M phase in U87 cells. This compound serves as a valuable tool for research focused on targeting EGFR in cancer therapy. -
FGFR2 ADC
Aprutumab ixadotin is an antibody-drug conjugate (ADC) that targets fibroblast growth factor receptor 2 (FGFR2). It combines a fully human anti-FGFR2 monoclonal antibody with an innovative non-cleavable linker conjugated to an Auristatin W derivative. This reagent is primarily utilized in research focused on advanced solid tumors, including FGFR2-positive gastric cancer and triple-negative breast cancer, facilitating the exploration of targeted therapies in these malignancies. -
Glycosphingolipid
Ganglioside GM1 (bovine) ammonium is a glycosphingolipid primarily located in the cell membranes of the vertebrate central nervous system. It provides neuroprotective effects by modulating N-methyl-D-aspartate receptor (NMDAR) activity, activating TrkA and ERK1/2 pathways, and reducing oxidative stress, cell apoptosis, and autophagy. This compound is valuable for research into neurological disorders, including traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease. -
Src/Tubulin Inhibitor
KX2-361 is an inhibitor of Src-kinase and tubulin polymerization. This compound exhibits significant anti-tumor activity and induces apoptosis in glioblastoma (GBM) cells. With good oral bioavailability and the ability to cross the blood-brain barrier in murine models, KX2-361 is a valuable tool for investigating Src-related signaling pathways and therapeutic strategies in cancer research. -
ACK1 Inhibitor
(R)-9b is a potent inhibitor of ACK1 tyrosine kinase, exhibiting an IC50 value of 56 nM. This compound selectively targets ACK1 while also exhibiting inhibitory effects on JAK2 and Tyk2 kinases. (R)-9b is valuable for research into hormone-regulated cancers, including prostate and breast cancer, providing a tool for understanding ACK1's role in cancer progression and treatment. -
CDK2/JAK2/FLT3 Inhibitor
(E/Z)-Zotiraciclib hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3, exhibiting IC50 values of 13 nM, 73 nM, and 56 nM, respectively. This orally active compound demonstrates significant efficacy in inhibiting the proliferation of various cancer cell lines. It is a valuable tool for research into therapeutic strategies targeting cell cycle regulation and signal transduction pathways in cancer. -
CDK2/JAK2/FLT3 Inhibitor
(E/Z)-Zotiraciclib citrate is a potent inhibitor targeting CDK2, JAK2, and FLT3 kinases. This compound demonstrates significant biological activity in disrupting cell cycle progression and signaling pathways associated with cell proliferation and survival. It is utilized in cancer research applications, particularly for studies involving hematological malignancies and solid tumors where these kinases are dysregulated. -
ITK/JAK3 Inhibitor
Modzatinib is a selective, covalent inhibitor targeting ITK and JAK3, demonstrating IC50 values of 8 nM and 23 nM, respectively. Its potent anti-inflammatory properties make it a valuable tool for research in autoimmune and inflammatory diseases, facilitating the exploration of therapeutic interventions in these areas. Researchers can leverage modzatinib to study the mechanistic roles of ITK and JAK3 in immune responses and disease pathology. -
IRAK4/IRAK1 Inhibitor
IRAK4 modulator-2 is a selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1, exhibiting IC50 values of 0.005 μM and 0.97 μM, respectively. This compound effectively disrupts IRAK-mediated signaling pathways, including JAK-STAT and NF-κB pathways, leading to a reduction in pro-inflammatory cytokine production, such as IL-1 and TNF. IRAK4 modulator-2 demonstrates potential for use in research focusing on autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. -
JAK2/FLT3 Inhibitor
Pacritinib hydrochloride is a selective inhibitor targeting JAK2 and FLT3, demonstrating inhibitory potency against wild-type JAK2 (IC50=23 nM), the JAK2V617F mutant (IC50=19 nM), and FLT3 (IC50=22 nM) as well as the FLT3D835Y mutant (IC50=6 nM). This compound is primarily utilized in research related to acute myeloid leukemia (AML) and myelofibrosis (MF), making it a valuable tool for studying these hematological malignancies and the associated signaling pathways. -
PROTAC FLT3/JAK2/BRD4 Degrader
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a potent PROTAC degrader that simultaneously targets FLT3, JAK2, and BRD4, exhibiting DC50 values of 5.23 nM, 0.678 nM, and 1.17 nM, respectively. It demonstrates significant antiproliferative activity against MV4;11 cells with an IC50 of 0.79 nM, inducing apoptosis in these cells. Additionally, PROTAC FLT3/JAK2/BRD4 Degrader-1 shows marked anti-tumor efficacy in MV4;11 xenograft models in NOD SCID mice. This compound is valuable for research into acute myeloid leukemia (AML). -
JAK2/FLT3 Inhibitor
SB1578 is a selective inhibitor of JAK2 and FLT3, exhibiting IC50 values of 46 nM and 60 nM, respectively. This compound demonstrates high selectivity for other kinase targets, making it a valuable tool for research. SB1578 is particularly useful in studying non-oncological indications, such as rheumatoid arthritis, offering insights into potential therapeutic applications in inflammatory diseases. -
CDK2/JAK2/FLT3 Inhibitor
Zotiraciclib hydrochloride is a novel small molecule inhibitor targeting cyclin-dependent kinase 2 (CDK2), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase 3 (FLT3). This reagent demonstrates anti-tumor activity by downregulating the Myc oncogene through CDK9 inhibition, contributing to reduced tumor growth. Zotiraciclib hydrochloride is particularly relevant for research into cancers capable of crossing the blood-brain barrier, and elevated levels of the MCL-1 protein may indicate its potential as a prognostic marker and therapeutic target in cancer studies. -
FLT3/JAK2/BRD4 Ligand
FLT3/JAK2/BRD4 ligand-1 is a specific ligand for the FLT3, JAK2, and BRD4 proteins. This compound facilitates the design and synthesis of proteolysis-targeting chimeras (PROTACs), specifically PROTAC FLT3/JAK2/BRD4 Degrader-1. It demonstrates potential applications in targeted protein degradation and cancer research, enabling innovative therapeutic strategies against malignancies associated with these targets. -
FLT3 Inhibitor
JI6 is a potent and selective FLT3 inhibitor, exhibiting IC50 values of approximately 40 nM for FLT3-WT, 8 nM for FLT3-D835Y, and 4 nM for FLT3-D835H. Additionally, JI6 demonstrates inhibitory activity against JAK3 and c-Kit, with IC50 values of around 250 nM and 500 nM, respectively. This compound serves as a valuable tool for research applications focused on acute myeloid leukemia. -
BET/JAK2/FLT3 Inhibitor
SG3-179 is a selective inhibitor of BET bromodomain proteins, with additional activity against JAK2 and FLT3. This compound effectively reduces HOXB13 protein expression, demonstrating potential relevance in the study of multiple myeloma (MM1.S). SG3-179 is a valuable tool for research involving epigenetic regulation and signaling pathways associated with hematological malignancies. -
FGFR1 Agonist
TCB-32 is a potent FGFR1 agonist with an EC50 of 0.88 μM, effectively activating the FGFR1 signaling pathway to enhance cell proliferation, notably through the ERK 1/2 cascade. This compound exhibits excellent thermal stability and can serve as a substitute for bFGF in serum-free cell culture environments. TCB-32 is applicable in research related to tissue repair and wound healing, making it suitable for studies investigating conditions such as psoriasis and eczema. -
FGFR3/BRAF Binder
2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose functions as a selective binder for Fibroblast Growth Factor Receptor 3 (FGFR3) and BRAF, playing a pivotal role in modulating pathways associated with cancer progression. Derived from Atractylodes japonica, this compound exhibits low cytotoxicity towards cancer cell lines, making it a suitable candidate for research applications focused on targeted cancer therapies and signaling pathway studies. Its unique structural characteristics enhance its potential for further exploration in drug development and therapeutic interventions. -
bFGF/FGFR1 Ligand
bFGF (119-126) is a peptide ligand that selectively targets FGFR1, disrupting the bFGF-FGFR1 interaction, which leads to inhibition of FGFR1 phosphorylation and subsequent downstream signaling pathways. This results in the promotion of apoptosis and suppression of cell proliferation, migration, angiogenesis, and metastasis. Additionally, when conjugated with a carrier, bFGF (119-126) enhances cellular uptake through FGFR-mediated endocytosis, serving as an effective FGFR-targeting agent. Its applications extend to research in various cancers, including lung cancer, breast cancer, glioblastoma, and ovarian cancer, particularly when combined with ultrasound and Doxorubicin to potentiate antitumor effects. -
FGFR3 Inhibitor
Dabogratinib is a selective inhibitor of FGFR3, displaying an IC50 of 11 nM. It demonstrates significant antitumor activity against urothelial carcinoma and various solid tumors by downregulating FGFR3 and ERK1/2 signaling pathways, leading to tumor growth inhibition and regression in FGFR3-altered xenograft models. Additionally, Dabogratinib enhances chondrocyte proliferation and differentiation, promotes endochondral bone formation, and improves craniofacial and spinal morphology. This compound is valuable for research into metastatic urothelial carcinoma, achondroplasia, and hypochondroplasia. -
FGFR2 Inhibitor
FGFR2-IN-2 is a selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), demonstrating inhibitory potency with an IC50 value of 29 nM against FGFR2, and 389 nM and 758 nM for FGFR1 and FGFR3, respectively. This compound exhibits potential in the study of FGFR-related signaling pathways and can be utilized in research focused on cancer therapeutics, particularly in tumors with aberrant FGFR2 activity. -
FGFR Inhibitor
FIIN-1 is a selective, irreversible inhibitor of fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4). It exhibits potent binding affinity, with Kd values of 2.8 nM for FGFR1, 6.9 nM for FGFR2, 5.4 nM for FGFR3, and 120 nM for FGFR4, alongside Kd values of 32 nM and 120 nM for Flt1 and Flt4, respectively. With biochemical IC50 values of 9.2 nM for FGFR1, 6.2 nM for FGFR2, 11.9 nM for FGFR3, and 189 nM for FGFR4, FIIN-1 is valuable for research applications focused on FGFR-related pathways in cancer and developmental biology. -
FGFR-β-klotho complex Activator
Efimosfermin alfa is a genetically modified variant of FGF21 that activates the FGFR1c/β-Klotho complex. This compound plays a critical role in metabolic regulation, specifically in the context of metabolic dysfunction-associated steatohepatitis, obesity, and mild hypertriglyceridemia. Its unique mechanism of action makes it a valuable tool for research exploring metabolic disorders and their associated pathways. -
FGFR1 Inhibitor
FGFR1 inhibitor-10 is a potent FGFR1 inhibitor with an IC50 value of 28 nM. It effectively inhibits the phosphorylation of FGFR1, leading to significant anti-angiogenic, anti-invasive, and anti-tumor activities. This compound is valuable for research applications focused on understanding FGFR1 signaling pathways and developing therapies for cancers characterized by aberrant FGFR1 activity. -
FGFR3 Inhibitor
FGFR3-IN-5 is a potent and selective inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3), exhibiting IC50 values of 3 nM for FGFR3, 44 nM for FGFR2, and 289 nM for FGFR1. This compound demonstrates effective inhibition of FGFR3 signaling pathways, making it a valuable tool for cancer research. FGFR3-IN-5 is suitable for studies investigating the role of FGFR3 in tumorigenesis and therapeutic response. -
FLT3/FGFR Inhibitor
MAX-40279 is a dual inhibitor targeting FLT3 and FGFR kinases, exhibiting potent activity against both wild-type and FLT3 mutants, including FLT3D835Y. This compound effectively inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 is valuable for research applications in acute myelogenous leukemia (AML), particularly in studying resistance mechanisms to existing therapies. -
FGFR (1-3) Inhibitor
CPL304110 is a selective inhibitor of fibroblast growth factor receptors FGFR1-3, demonstrating potent activity with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for each receptor, respectively. This orally active compound is valuable in research applications aimed at understanding FGFR signaling pathways and their role in various cancers and pathological conditions. Its efficacy in modulating FGFR activity makes it a valuable tool for investigating therapeutic strategies targeting fibroblast growth factor receptor-mediated processes. -
FGFR2 Inhibitor
Lirafugratinib hydrochloride is an orally active, irreversible inhibitor specifically targeting FGFR2 with an IC50 of 3 nM. It covalently binds to the cysteine residue Cys491, effectively addressing FGFR2 primary alterations and resistance mutations. This compound is designed to induce tumor regression while exhibiting minimal impact on other FGFR family members, making it valuable for research in cancer therapeutics focused on FGFR-dependent malignancies. -
FGFR3-TACC3 Degrader
SNIPER(TACC3)-11 is a potent degrader of the FGFR3-TACC3 fusion protein, utilizing targeted protein degradation to reduce its levels within cells. This compound effectively suppresses the proliferation of cancer cells that express the FGFR3-TACC3 fusion, making it a valuable tool for research related to targeting oncogenic protein fusions in cancer therapy. Its potential applications include studies in cancer biology and the development of novel therapeutic strategies against FGFR3-TACC3-positive tumors. -
FGFR Inhibitor
FGFR2-IN-1 is a selective inhibitor of Fibroblast Growth Factor Receptor 2 (FGFR2), exhibiting an IC50 of 140 nM. This compound effectively modulates FGFR2 activity, demonstrating significant biological activity relevant to cancer research. It is utilized in various studies focusing on tumorigenesis and the role of FGFR signaling pathways in malignancies. -
PDGFR Inhibitor
(Z)-Orantinib is a selective, orally active ATP-competitive inhibitor targeting PDGFRβ, as well as Flk‐1/KDR and FGFR1, with IC50 values of 0.008 µM, 2.1 µM, and 1.2 µM, respectively. This compound exhibits significant antiangiogenic and antitumor properties, effectively inducing regression of established tumors. It is a valuable tool for research applications focused on cancer biology and the mechanisms of angiogenesis. -
FGFR4 Inhibitor
FGFR4-IN-5 is a selective covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) with an IC50 of 6.5 nM. It demonstrates significant anti-tumor activity in vivo, making it a valuable tool for research focused on hepatocellular carcinoma. This compound is ideal for studies investigating FGFR4-mediated signaling pathways and therapeutic strategies in cancer treatment. -
FGFR1 Inhibitor
CYY292 is an FGFR1 inhibitor that targets the FGFR1/AKT/Snail signaling pathway, demonstrating significant effects in glioblastoma (GBM) cells. This compound effectively inhibits cancer cell proliferation and reduces epithelial-mesenchymal transition, stemness, invasion, and migration in a dose-dependent manner. CYY292 is a valuable reagent for research applications aimed at understanding the molecular underpinnings of GBM and exploring potential therapeutic strategies. -
FGFR2 Inhibitor
FGFR2-IN-3 is a selective inhibitor of fibroblast growth factor receptor 2 (FGFR2). It exhibits strong binding affinity, facilitating critical interactions and inducing conformational alterations in the receptor. This compound is primarily utilized in cancer research, particularly in investigations focused on tumor biology and signaling pathways involving FGFR2. -
VEGFR2 Inhibitor
JK-P3 is a selective inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) with IC50 values of 7.83 μM for VEGFR2, 27 μM for FGFR1, and 5.18 μM for FGFR3. It effectively blocks VEGF-A-induced VEGFR2 activation and downstream signaling pathways, demonstrating inhibition of endothelial cell migration and angiogenesis in vitro. Additionally, JK-P3 suppresses fibroblast growth factor receptor kinase activity, contributing to its anti-angiogenic properties and making it a valuable tool for research in vascular biology and cancer therapeutics. -
VEGFR/FGFR Inhibitor
Lucitanib dihydrochloride is a selective dual inhibitor targeting VEGFR and FGFR, demonstrating potent inhibition of VEGFR1, VEGFR2, VEGFR3, FGFR1, and FGFR2 with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively. This inhibitor plays a critical role in regulating angiogenesis and tumor growth, making it valuable for research in cancer biology and therapeutic development. Lucitanib dihydrochloride is suitable for studies focused on vascular endothelial growth factor signaling pathways and fibroblast growth factor signaling, contributing to the understanding of tumor microenvironment interactions. -
FGFR1/2/3 Inhibitor
TYRA-200 is an orally active inhibitor of FGFR1, FGFR2, and FGFR3. This compound demonstrates dose-dependent tumor regression in mice models expressing both wild-type and mutant FGFR2. TYRA-200 serves as a valuable tool for investigating advanced or metastatic intrahepatic cholangiocarcinoma and other solid tumors driven by FGFR2 mutations in preclinical research. -
PROTAC FGFR1/2 Degrader
DGY-09-192 is a PROTAC degrader targeting FGFR1 and FGFR2, demonstrating DC50 values of 4.35 nM and 70 nM, respectively. This compound selectively degrades both wild-type FGFR1/2 and various FGFR2 fusion proteins, such as FGFR2-PHGDH and FGFR2-OPTN. By suppressing downstream FGFR signaling, DGY-09-192 effectively reduces the phosphorylation of key targets including FRS2 Y196 and ERK1/2 T202/Y204, making it a valuable tool for investigating FGFR-driven malignancies in both in vitro and in vivo studies. -
FGFR Activator
FGL peptide is a fibroblast growth factor receptor (FGFR) activator that effectively penetrates the blood-brain barrier. It initiates NCAM-FGFR and FGFR1 signaling pathways, which modulate the expression of genes involved in apoptosis, signal transduction, and metabolic regulation. FGL peptide is primarily utilized in research focused on traumatic brain injury, offering insights into its underlying molecular mechanisms and potential therapeutic targets. -
FGFR1 Agonist
TCB-32 hydrochloride is an FGFR1 agonist with an EC50 of 0.88 μM. This compound effectively enhances cell proliferation by activating the FGFR1 signaling pathway, notably promoting downstream ERK 1/2 activity. With excellent thermal stability, TCB-32 hydrochloride serves as a viable replacement for bFGF in serum-free cell culture media. Its applications extend to tissue repair and the study of wound healing in diseases such as psoriasis and eczema. -
FGFR Inhibitor
Derazantinib Racemate is an ATP-competitive inhibitor targeting fibroblast growth factor receptors (FGFR1-3). This compound demonstrates potent inhibitory activity in chondrocytes, with IC50 values of 4.5 nM for FGFR1, 1.8 nM for FGFR2, and 4.5 nM for FGFR3. It is suitable for research applications focused on FGFR-related signaling pathways and their implications in various cancers and diseases. -
FLT3/FGFR Inhibitor
MAX-40279 hemiadipate is a dual inhibitor of FLT3 and FGFR kinases, exhibiting oral bioactivity. This compound effectively targets multiple FLT3 mutants, including FLT3D835Y, and has the potential to overcome resistance against existing treatments. Inhibition of NDRG1 phosphorylation at Ser330 and suppression of endothelial-to-mesenchymal transition (EndMT) further characterize its biological activity. MAX-40279 hemiadipate is a valuable tool for research into acute myelogenous leukemia (AML).
